Hasil Pencarian - Joao Victor Alessi

  • Menampilkan 1 - 2 hasil dari 2
Perbaiki Hasil
  1. 1
    312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%

    312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90% oleh Mark Awad, Giuseppe Lamberti, Lynette Sholl, Joao Victor Alessi, Stephanie Alden, Victor Vaz, Adriana Barrichello

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer

    67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer oleh Mark Awad, Gonzalo Recondo, Giuseppe Lamberti, Scott Rodig, Joao Victor Alessi, Victor Vaz, Adriana Barrichello, Yvonne Lin-Liu, Hersh Gupta, Xinan Wang, Andrew Cherniack, Kristen Felt

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: